A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months

Abstract Background To evaluate the long-term efficacy and safety of fremanezumab over a 2-year period in a real-world setting. Methods This retrospective, observational, single-center cohort study included 165 patients with episodic migraine (EM) or chronic migraine (CM) who received fremanezumab t...

Full description

Bibliographic Details
Published in:	Neurological Research and Practice
Main Authors:	Shiho Suzuki, Keisuke Suzuki, Yasuo Haruyama, Hiroaki Fujita, Tomohiko Shiina, Saro Kobayashi, Mukuto Shioda, Ryotaro Hida, Koichi Hirata
Format:	Article
Language:	English
Published:	BMC 2025-06-01
Subjects:	Migraine Migraine days per month Fremanezumab Calcitonin gene-related peptide monoclonal antibody
Online Access:	https://doi.org/10.1186/s42466-025-00395-y

Similar Items

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
by: Shiho Suzuki, et al.
Published: (2023-07-01)

Real-world effectiveness of erenumab in Japanese patients with migraine
by: Keisuke Suzuki, et al.
Published: (2024-02-01)

The effect of calcitonin gene-related peptide monoclonal antibodies on restless legs syndrome in patients with migraine
by: Keisuke Suzuki, et al.
Published: (2025-02-01)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-05-01)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-04-01)

Fremanezumab in the treatment of migraines: evidence to date
by: Robblee J, et al.
Published: (2019-08-01)

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

Can calcitonin gene‐related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
by: Keisuke Suzuki, et al.
Published: (2024-06-01)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
by: Seiya Ohtani, et al.
Published: (2023-11-01)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Noboru Imai, et al.
Published: (2023-09-01)

Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
by: Bixi Gao, et al.
Published: (2020-05-01)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

Fremanezumab in real-life clinical practice: specialized headache center experience
by: Yu. E. Azimova, et al.
Published: (2024-06-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
by: G. N. Belskaya, et al.
Published: (2024-02-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study
by: Juan Tudela‐Tomas, et al.
Published: (2024-07-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY<sup>®</sup>) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study
by: Aksana Jones, et al.
Published: (2021-05-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
by: Piero Barbanti, et al.
Published: (2023-03-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01)

Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: A real-world observational study in Japan
by: Shiho Suzuki, et al.
Published: (2023-10-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01)

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-03-01)

Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies
by: Ani C. Khodavirdi, et al.
Published: (2024-08-01)

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis
by: Armin Scheffler, et al.
Published: (2024-07-01)

Efficacy and continuability of 675 mg fremanezumab administration over 2 years
by: Shohei Yoshida, et al.
Published: (2025-03-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
by: Raffaele Ornello, et al.
Published: (2021-03-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
by: Hans-Christoph Diener, et al.
Published: (2025-02-01)

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
by: Danilo Antonio Montisano, et al.
Published: (2024-04-01)